MYCN-amplified stage 2/3 neuroblastoma: Excellent survival in the era of anti-G(D2) immunotherapy Journal Article
| Authors: | Kushner, B. H.; LaQuaglia, M. P.; Modak, S.; Wolden, S. L.; Basu, E. M.; Roberts, S. S.; Kramer, K.; Yataghene, K.; Cheung, I. Y.; Cheung, N. V. |
| Article Title: | MYCN-amplified stage 2/3 neuroblastoma: Excellent survival in the era of anti-G(D2) immunotherapy |
| Abstract: | High-risk neuroblastoma (HR-NB) includes MYCN-amplified stage 2/3, but reports covering anti-GD2 immunotherapy, which recently became standard for HR-NB, do not provide details on this subset. We now report on all 20 MYCN-amplified stage 2/3 patients who received induction chemotherapy at our center during the era of consolidation with anti-GD2 antibody 3F8/ granulocyte-macrophage colony-stimulating factor (GM-CSF) (2000-2015). Early in this period, consolidation included autologous stem-cell transplantation (ASCT). Event-free survival (EFS) and overall survival (OS) were estimated using Kaplan-Meier analyses. With induction, 19/20 (95%) patients achieved complete/very good partial remission (CR/VGPR) but one had progressive disease with early death. One responder did not receive consolidation and died of relapse. Five-year post-diagnosis EFS/OS rates for all 20 patients were 72%/84%. The 18 CR/VGPR patients who received consolidation had EFS/OS 81%/94% at five years from starting 3F8/GM-CSF: 4/4 ASCT patients remained relapse-free, while 11/14 non-ASCT patients remained relapse-free and two of the three relapsed patients achieved 2nd CR (consolidated by retreatment with 3F8/GM-CSF) and remained in 2nd CR at 36+ and 95+ months post-relapse. The 14 non-ASCT patients had EFS/OS 73.5%/93% at five years from starting 3F8/GM-CSF. This subset appears to have a good prognosis with contemporary multi-modality therapy, possibly even without ASCT. © Kushner et al. |
| Keywords: | adolescent; adult; cancer survival; child; clinical article; controlled study; event free survival; school child; aged; middle aged; young adult; unclassified drug; overall survival; cancer staging; cancer immunotherapy; multiple cycle treatment; gene amplification; granulocyte macrophage colony stimulating factor; cohort analysis; autologous stem cell transplantation; monoclonal antibody; cancer regression; cytokine; neuroblastoma; monoclonal antibody 3f8; autologous transplantation; mycn gene; cancer prognosis; anti-gd2 antibody; human; male; female; article; mycn amplification |
| Journal Title: | Oncotarget |
| Volume: | 8 |
| Issue: | 56 |
| ISSN: | 1949-2553 |
| Publisher: | Impact Journals |
| Date Published: | 2017-11-10 |
| Start Page: | 95293 |
| End Page: | 95302 |
| Language: | English |
| DOI: | 10.18632/oncotarget.20513 |
| PROVIDER: | scopus |
| PMCID: | PMC5707022 |
| PUBMED: | 29221128 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 4 December 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work